Mark Anderson

Professor, University of California, San Francisco
Director, Diabetes Center at UCSF @AtUcsf
President, Fed of Clinical Immunology Societies @FOCISimmunology

[Mark Anderson @MAndersonUCSF]

@theNAMedicine @Englandsk785 @WUSTLmed Congrats Sarah!

[Roose Lab UCSF @roose_jeroen]

LUCKY when one can combine work with friendship. I am very lucky @ucsfhealth w. friends @immunox @UCSFAging & friendly relationships with @UCSF leadership. Excited how this "group of friends" imagined a 2017 dream & very grateful to Bakar family and others to make this reality.

[Mark Anderson @MAndersonUCSF]

@NadavAhituv @GeneticsSociety Congrats!!!

[UC San Francisco @UCSF]

Early in the pandemic, kids were hospitalized with a mysterious disease, MIS-C. A team led by @DrAaron14 @MAndersonUCSF @czbiohub discovered how mild COVID led to MIS-C, hinting at what might go wrong in autoimmune diseases like #MS. @BCH_InTheNews @stjude https://t.co/MNJTXkhd37

[Mark Anderson @MAndersonUCSF]

Scientists Get to the Bottom of COVID’s Worst Pediatric Complication https://t.co/FpVCdAXyJ7

[Mark Anderson @MAndersonUCSF]

Proud of our team that unlocked this terrible complication of COVID-19 in children. @AtUcsf @UCSF @immunox

https://t.co/cDBFrRYvLh

[Mark Anderson @MAndersonUCSF]

Congrats to our team in the UCSF Diabetes Center!

[Suneil Koliwad @SuneilKoliwad]

Microglia can be manipulated to impact CNS control of weight gain and glucose control. But what do hypothalamic microglia do? We now explore this in newborn mice, with fascinating results. Congrats to @MValdearcos and our outstanding team! @AtUcsf @NorcUcsf @UCSF

[Journal of Experimental Medicine @JExpMed]

Insights: @DrCindyMa & @stutangye discuss new study from @MACattackLab (https://t.co/4LLX8joriS) that proposes a role for dysregulated IL-22 production by Th17 cells in causing some aspects of immune-mediated skin inflammation in #STAT3GOF syndrome. https://t.co/oFtMQJ4cjs

[Mark Anderson @MAndersonUCSF]

@LauferTerri @s_apostolidis @PennRheum Congrats!!!!

[Mark Anderson @MAndersonUCSF]

Great piece on all of the excitement around Ozempic and GLP-1 agonists. Great job Suneil!

[Diabetes Center at UCSF @AtUcsf]

Weight loss drug article in @UCSF Magazine featuring UCSF Diabetes Center professor and Chief of Endocrinology @SuneilKoliwad

https://t.co/Qz9Tp9WKVU

[Mark Anderson @MAndersonUCSF]

Honored and thrilled for this recognition

[Diabetes Center at UCSF @AtUcsf]

UCSF Diabetes Center Director Mark Anderson Receives 2024 Cancer Research Institute Coley Award @MAndersonUCSF @CancerResearch

https://t.co/pHliUajTeH

[Mark Anderson @MAndersonUCSF]

@j_eyquem @Satpathology @pewtrusts Congrats Justin!!!

[Mark Anderson @MAndersonUCSF]

Excited to share new collaborative work on the autoreactome that just came out in JCI

https://t.co/4wJsiWVhZe

[Diabetes Center at UCSF @AtUcsf]

"Decoding gene regulation with CRISPR perturbations" by @McManus_Lab postdoc Stefan Oberlin published in @NatureBiotech

[Mark Anderson @MAndersonUCSF]

Excited to share some new collaborative work with the Kappler lab on how thymic tolerance to insulin is maintained in a model of T1 Diabetes.
Aire mediates tolerance to insulin through thymic trimming of high-affinity T cell clones | PNAS https://t.co/G4ieFy98hb

[Mark Anderson @MAndersonUCSF]

Excited to be part of a team that identified a rare family with a defect in PDL1 that has a strong link to type 1 diabetes and other immune dysregulation. https://t.co/h6C98kWQpz

[FOCIS @FOCISimmunology]

Finalize & Submit your abstract ahead of time ✔️ There's only 3 days remaining to submit your research and be a part of the FOCIS 2024 Annual Meeting!

Don't wait - submit today ⏳: https://t.co/m2pdB6hPDI

[Mark Anderson @MAndersonUCSF]

Congrats to Mianmian and Tony on this important collaborative work on thymic selection of autoreactive T cells!

Tracking the role of Aire in immune tolerance to the eye with a TCR transgenic mouse model | PNAS https://t.co/9x2bWOFLbK

[Mark Anderson @MAndersonUCSF]

@KimrynRathmell @MACattackLab Congrats Kim and best wishes!!!

[Chan Zuckerberg Biohub Network @czbiohub]

New in @Nature: #COVID patients with specific mutations in NFKB2 gene develop antibodies to type I interferons, which are associated with a severe disease course, often involving hospitalization and ICU care. 🧵 1/5